Fig 3. Inhibition of the pathogenesis of demyelinating disease and viral loads in mice treated with a PGE₂ inhibitor, AH23848.

A. TMEV was inoculated by intracerebral injection (1x10⁶ PFU) into AH23848-treated SJL mice (n = 10) and DMSO vehicle-treated control SJL mice (n = 9) at 1, 5, and 8 dpi. The percentage of affected mice and the mean clinical scores (+/- SD) were monitored weekly. Clinical scores of individual mice were shown in S1 Table. The two-tailed p value between the control and AH23848-treated groups was very significant (p < 0.0059) based on the paired t test of the mean clinical cores (t = 4.582 with 5 degrees of freedom) between days 21 and 56 post-infection. B. Viral load levels in the CNS of AH23848-treated and control mice were assessed at 8 and 21 dpi using qPCR. The significance of the difference was assessed using two-tailed unpaired Student t test. **, P < 0.01; ***, P < 0.001.